Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes

Background Patients with paraneoplastic syndromes (PNS) are excluded from clinical trials involving immune checkpoint inhibitors (ICIs) due to safety concerns. Moreover, real-world data on efficacy and safety is scarce.Methods In this retrospective study, data were collected on patients with PNS and...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Lucia Kwak, So Yeon Kim, Guru Sonpavde, Elad Sharon, Abdul Rafeh Naqash, Alessio Cortellini, Rana R McKay, Toni K Choueiri, Thomas Marron, Amin H Nassar, Jeffrey A Sparks, Kaushal Parikh, Frank Aboubakar Nana, Jenny Linnoila, Shruti Gupta, Nicole R LeBoeuf, Elio Adib, Ahmad Al-Hader, Edward El-Am, Dory Freeman, Ahmed Bilal Khalid, Marita Salame, Elias Bou Farhat, Arjun Ravishankar, Bachar Ahmad, David Kaldas, Andrea Malgeri, Ole-Petter R Hamnvik, Thomas Dilling, Elie Najem, Talal El Zarif, Serena Rahme, Caiwei Zhong, Tarek H Mouhieddine
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMJ Publishing Group 2024-03-01
coleção:	Journal for ImmunoTherapy of Cancer
Acesso em linha:	https://jitc.bmj.com/content/12/3/e008724.full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!